A Case of Duodenal Neuroendocrine Carcinoma Treated with Amrubicin as Second-line Chemotherapy
DOI:
https://doi.org/10.15403/jgld.2014.1121.243.inoKeywords:
duodenal neuroendocrine carcinoma, amrubicin, chemotherapyAbstract
We present the case of a Japanese man in his 60s with duodenal neuroendocrine carcinoma with distant metastases. Chemotherapy with irinotecan plus cisplatin was initiated as a first-line regimen. However, disease progression was observed after only two cycles. Therefore, amrubicin was administered as a second-line chemotherapy. The patient showed a long-term effect of amrubicin therapy, and the best response was a partial response after seven cycles. For duodenal neuroendocrine carcinoma, amrubicin therapy can be considered an effective treatment option as salvage chemotherapy.
Downloads
Published
2015-09-01
How to Cite
1.
Inoue T, Sano H, Mizushima T, Nishie H, Iwasaki H, Okumura F. A Case of Duodenal Neuroendocrine Carcinoma Treated with Amrubicin as Second-line Chemotherapy. JGLD [Internet]. 2015 Sep. 1 [cited 2025 Jul. 9];24(3):379-82. Available from: https://www.jgld.ro/jgld/index.php/jgld/article/view/1195
Issue
Section
Case Reports